Victory Capital Management Inc. reduced its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 59.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 115,932 shares of the company’s stock after selling 168,512 shares during the quarter. Victory Capital Management Inc.’s holdings in Moderna were worth $4,820,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. State Street Corp boosted its stake in Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after purchasing an additional 1,823,276 shares in the last quarter. Geode Capital Management LLC boosted its position in Moderna by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock worth $470,670,000 after acquiring an additional 178,115 shares during the period. Wellington Management Group LLP increased its stake in Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after buying an additional 906,114 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Moderna by 0.5% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock worth $260,023,000 after acquiring an additional 19,819 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in Moderna by 6.2% in the third quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock valued at $205,431,000 after purchasing an additional 178,939 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.
Moderna Price Performance
Shares of MRNA stock opened at $34.62 on Friday. The stock has a market cap of $13.36 billion, a PE ratio of -3.73 and a beta of 1.86. The stock has a 50-day moving average of $35.94 and a 200-day moving average of $47.37. Moderna, Inc. has a one year low of $29.25 and a one year high of $170.47.
Analyst Ratings Changes
Read Our Latest Report on MRNA
Moderna Company Profile
Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Recommended Stories
- Five stocks we like better than Moderna
- What is a SEC Filing?
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Financial Services Stocks Investing
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- What Are Growth Stocks and Investing in Them
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Want to see what other hedge funds are holding MRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Moderna, Inc. (NASDAQ:MRNA – Free Report).
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.